Fenofibrate相关论文
PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by
Recent studies show that intracellular accumulation of cholesterol leads to acquired resistance to gefitinib in non-smal......
Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroref
Fenofibrate,an agonist for peroxisome proliferator-activated receptor alpha (PPAR-α),lowers blood pressure,but whether ......
To prepare fenofibrate nanoliposome(FNB-Nanolipo)and investigate its characterizations,oral pharmacokinetic profiles as ......
二型糖尿病是以胰岛素抵抗为主的损害多器官的慢性疾病，而胰岛素同样在骨骼发育中起重要作用。二型糖尿病患者的BMD值与正常人相比......
Fenofibrate Nanoliposome: Preparation and Its Inhibition Effects on Nonalcoholic Fatty Liver Disease
Objective: To prepare fenofibrate nanoliposome (FNB-Nanolipo) and investigate its characterizations, oral pharmacokineti......
Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in nor
AIM To investigate the effects of dietary intake of Fructus Schisandrae chinensis (FSC), both aqueous and ethanolic extr......
A novel mouse model of combined hyperlipidemia associated with fatty liver and steatohepatitis gener
AIM To create a novel mouse model of combined hyperlipidemia using a modeling agent (MA) made of a mixture of schisandri......
AIM To study the pharmacokinetics and bioequivalence of domestic and imported micronised fenofibrate capsual in healthy ......
目的 探讨过氧化酶增殖物激活受体α(PPARα)激动剂非诺贝特对糜酶介导的大鼠心脏成纤维细胞(CFs)增殖的影响及作用机制.方法 用胰......
目的 探讨过氧化物酶体增殖物激活受体α(PPARα)激动剂非诺贝特对糜酶诱导的心脏成纤维细胞(CFs)胶原合成的影响及细胞内信号转导......
Age-related decrease in expression of peroxisome proliferator-activated receptor α and its effects o
...
...
In vitro-in vivo correlation(IVIVC)of solid dosage forms should be established basically between in vitro and in vivo di......
13名 2型糖尿病人其中男 5,女 5,平均年龄 :6 0 0± 6岁 ,体重指数 30 0± 30ｋｇ/ｍ2 ,病程 12± 7年 ,血红蛋白ＡＩＣ7 3± 1 1% ,ＬＤＣ -Ｃｈ 135ｍｇ/ｄＬ ......
目的 探讨过氧化物酶体增殖物激活受体α(PPARα)活化对异丙肾上腺素(Iso)所致大鼠急性心.肌缺血性损伤的保护作用及作用机制.方法......
目的 观察非诺贝特治疗糖尿病视网膜病变合并肾病的临床疗效.方法 28例(56眼)2型糖尿病患者并发糖尿病视网膜病及肾病在控制血糖基......
目的探讨不同剂量阿托伐他汀联合非诺贝特对混合型高脂血症患者的血脂及预后的影响。方法选择混合型高脂血患者120例，通过随机数字......
2例行腹膜透析的女性患者(例1 52岁，例2 57岁)因血清三酰甘油增高服用非诺贝特200 mg/d，分别于用药6和8 d后出现下肢及肩背部肌肉酸......
Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoho
Nonalcoholic fatty liver disease (NAFLD) is regarded as the most common liver disease with no approved therapeutic drug ......
目的 探讨非诺贝特联合吡格列酮在初诊青少年代谢综合征(MS)治疗中的近期及远期疗效.方法 按国际糖尿病联盟(IDF)关于MS防治建议诊......
以Silymarin和Fenofibrate配成的复方能显著地降低高血脂症大鼠血清TC、LDL-c和VLDL-c,提高HDL-c的血浓度,使高血脂症大鼠血清脂蛋......
目的:观察非诺贝特联合贝那普利对扩张型心肌病并发慢性心力衰竭的临床疗效.方法:将62例患者随机分成对照组和观察组,对照组给予常......
采用流化床包衣法制备难溶性药物非诺贝特(FNB)-PEG6000的固体分散体.差示扫描量热法和X-射线粉末衍射法对固体分散体中非诺贝特的......
溶剂挥发法制备纳米骨架具有有机溶剂残留、环境污染、需要防爆保护等缺点.本文使用多孔二氧化硅Sylysia(R)350 (S350)和pH敏感材......
目的:用淀粉源介孔碳材料(SMC)改善非诺贝特(FNB)的溶出速率,并提高其口服生物利用度。方法:以介孔二氧化硅FDU作为模板制备SMC,通......
目的探讨非诺贝特对华法林抗凝作用的影响、作用机制和处理方法。方法 1位78岁老年男性患者长期稳定服用华法林抗凝治疗,在服用非......
目的制备介孔二氧化硅纳米粒(mesoporous silica nanoparticles,HK)增溶型非诺贝特(fenofibrate,FNB)片剂并进行体内外研究。方法......
目的:比较4种抗绝经后妇女原发性高脂血症方案的临床疗效和安全性,用药物经济学方法进行成本-效果分析。方法:采用随机对照临床研......
,High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal m
Aim: To investigate the effects of bifendate on serum and hepatic lipids level in rabbits and mice. Methods: Animals wer......
,Chronic palmitate exposure inhibits AMPKαand decreases glucose-stimulated insulin secretion from β-
Aim:Adenosine monophosphate-activated protein kinase (AMPK), a vital regu-lator of glucose metabolism, may affect insuli......
,Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperli
...
The effect of hyperlipidemia and inflammation on endothelial functions was studied.The enrolled included control(basic c......
目的 观察微粒化非诺贝特与阿托伐他汀对高脂血症合并高尿酸血症的治疗效果。方法 55例高血脂症合并高尿酸血症患者随机分为两组。......
Inhibitory Effects of Fenofibrate on Plasminogen Activator Inhibitor-1 Expression in Human Endotheli
The effects of fenofibrate on plasminogen activator inhibitor-1 (PAI-1) expression in human umbilical endothelial cell-d......
Fenofibrate Pre-treatment Suppressed Inflammation by Activating Phosphoinositide 3 Kinase/Protein Ki
...
目的 观察非诺贝特治疗中心性浆液性脉络膜视网膜病变的(central serous chorioretinopathy,CSC)临床疗效.方法 72例(72眼)CSC患者......
目的 观察过氧化酶增殖物激活受体(PPAR α)配体非诺贝特对四氯化碳(CCl4)诱导的小鼠肝纤维化的作用,并探讨其可能的机制.方法 26......
目的通过高脂饲料喂养SD大鼠建立非酒精性脂肪性肝病（NAFLD）模型，观察过氧化物酶体增殖物激活受体（PPAR）激动剂非诺贝特对NAFLD大鼠肝脂......
Age-related decrease in expression of peroxisome proliferator-activated receptor α and its effects o
Background Ageing is associated with increased incidence of dyslipidemia. To investigate potential molecular mechanisms......
Role of peroxisome proliferator-activated receptor a activation in acute myocardial damage induced b
Background Peroxisome proliferator-activated receptor(PPAR)a is one of the subtypes of PPARs.It regulates metabolism of ......
目的 观察非诺贝特咀嚼片治疗高脂血症的有效性和安全性.方法 在北京五所医院选择血浆甘油三酯水平≥2.26 mmol/L的患者100例,按随......
目的：探讨非诺贝特对酿酒酵母基因表达谱的影响，在基因表达水平上分析其作用机理。方法：采用非诺贝特（100μg/mL）处理酿酒酵母90min后，抽......
目的 比较非诺贝特与多烯磷脂酰胆碱治疗非酒精性脂肪肝(NAFLD)的临床疗效.方法 将86例非酒精性脂肪肝患者随机分为治疗组(45例)和......
目的观察二氯醋酸二异丙胺(DIPA)对2型糖尿病(T2DM)患者脂代谢紊乱等的影响及安全性。方法对辽宁地区8个中心的TG≥4.0 mmol/L的T2......
目的 研究吉非罗齐、非诺贝特和苯扎贝特3种贝特类药物对心、脑血管事件的作用.方法 系统性检索Cochrane图书馆临床对照试验数据库......
Objective To demonstrate the clinical efficacy of micronized fenofibrate on mildly-moderately elevated LDL-C levels and......
目的 观察不同浓度非诺贝特对高糖培养的足细胞的影响,探讨糖尿病肾病(DN)的早期机制. 方法 分离收集大鼠肾小球并进行足细胞原代......
目的：探讨非诺贝特和吡格列酮联合应用对于代谢综合征患者动脉粥样硬化的影响。方法242例代谢综合症患者分层随机编入基础治疗组(n=......
